A randomized controlled trial testing a virtual program for Asian American women breast cancer survivors
A culturally tailored virtual program could meet the survivorship needs of Asian American women breast cancer survivors (AABC). This study aims to determine the efficacy of a culturally tailored virtual information and coaching/support program (TICAA) in improving AABC’s survivorship experience. A randomized clinical trial (NCT02803593) was conducted from January 2017 to June 2020 among 199 AABC. The intervention group utilized TICAA and the American Cancer Society [ACS] website while the control group used only ACS website for 12 weeks. The outcomes were measured using the SCNS-34SF (needs; primary), the MSAS-SF (symptoms; secondary), and the FACT-B (quality of life; secondary). The data were analyzed using an intent-to-treat approach. The intervention group showed significant reductions in their needs from the baseline (T0) to post 4 weeks (T1) and to post 12 weeks (T2). Although the changes were not statistically significant, the intervention group had decreased symptoms from T0 to T2 while the control group had an increase in their symptoms. The intervention group had a significant increase in their quality of life from T0 to T2. A culturally tailored virtual program could therefore improve quality of life in AABC patients. Trial Registration: To Enhance Breast Cancer Survivorship of Asian Americans (TICAA), NCT02803593,
Top-30
Journals
|
1
|
|
|
Cancer Nursing
1 publication, 11.11%
|
|
|
Clinical Psychology Review
1 publication, 11.11%
|
|
|
npj Digital Medicine
1 publication, 11.11%
|
|
|
BMJ Quality and Safety
1 publication, 11.11%
|
|
|
Breast
1 publication, 11.11%
|
|
|
Journal of Cancer Education
1 publication, 11.11%
|
|
|
TrAC - Trends in Analytical Chemistry
1 publication, 11.11%
|
|
|
International Journal of Women's Health
1 publication, 11.11%
|
|
|
Journal of Clinical and Translational Science
1 publication, 11.11%
|
|
|
1
|
Publishers
|
1
2
3
|
|
|
Elsevier
3 publications, 33.33%
|
|
|
Springer Nature
2 publications, 22.22%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 11.11%
|
|
|
BMJ
1 publication, 11.11%
|
|
|
Taylor & Francis
1 publication, 11.11%
|
|
|
Cambridge University Press
1 publication, 11.11%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.